Developer docs
API playgroundTry for free, no card

Search company profiles

Protogenix, Inc

Full company profile

uuid0002por

Namestring
Protogenix, Inc
Legal namestring
Protogenix Inc.
Websiteurl
proto-genix.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Protogenix, Inc. is a privately held, pre-revenue biotechnology company developing a recombinant protein production platform intended to replace mammalian-based production systems. The company was founded in 2021 as a Delaware corporation and is headquartered in Ithaca, New York, operating with a small team of 1-10 employees. Its product is not yet commercialized; the corporate website (proto-genix.com) currently displays a 'Coming Soon' placeholder alongside the tagline 'The Future of Recombinant Protein Production,' and no named products, patents, or specific technical disclosures have been made public.

The company's core offering centers on a proprietary recombinant protein production technology. No specific upstream process, host system, or platform architecture has been publicly disclosed, and there are no documented patents, trademarks, certifications, or third-party validations in the input. Distribution is planned for a global footprint via direct (enterprise) sales once the platform launches, and the company has built basic digital infrastructure — a website with cookie-based analytics and a privacy-policy-anchored email/newsletter channel — to support pre-launch demand generation.

Protogenix's business model has not yet been articulated in commercial terms. The company is currently pre-revenue, with no disclosed pricing, no named customers, and no segment-level revenue mechanics. Its operating activity consists of product development and capital formation: approximately $1.97 million has been raised across four rounds between April 2023 and February 2026, including a seed round led by SOSV (formerly IndieBio) in 2023, and an SEC Form D filed in February 2026 seeking up to an additional $4.2 million under Rules 506(b) and 506(c). Use of proceeds is allocated to working capital and product development, with roughly $364,000 earmarked for payments to executive officers, directors, or promoters.

Short descriptiontext

Protogenix, Inc. is a pre-revenue biotechnology company developing a proprietary recombinant protein production platform intended to replace mammalian-based systems, headquartered in Ithaca, New York, with first product launch pending.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersIthaca, United States
HQ citystring
Ithaca
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant protein production, biotechnology platform, protein expression systems, biopharmaceutical manufacturing, life sciences technology
Industry2 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology — Recombinant Protein Production
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biotechnology Products
TypeSubscription Recurring
Description

Protogenix is a biotechnology company developing recombinant protein products. As a pre-revenue company currently raising seed capital, the expected revenue model would involve commercializing biotechnology products, though specific revenue mechanics are not yet disclosed.

sec.gov
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Protogenix is developing a novel platform for recombinant protein production intended to replace the conventional mammalian protein expression system. The company is in pre-commercialization stage, with its product offering not yet launched (website displays a 'Coming Soon' page) and is currently raising seed capital for product development and working capital.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Protogenix, Inc is a Delaware-incorporated biotechnology company founded in 2021 and based in Ithaca, New York, focused on recombinant protein production. The company's website currently displays a 'Coming Soon' message, indicating the product is in development stage. No specific named products, modules, or distinct offerings have been publicly launched or detailed in the available source material.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ORF Genetics uses barley-grain-based expression for recombinant proteins, including growth factors and cytokines. It is a direct non-mammalian production competitor in the recombinant protein space.

TypeDirect peer
Description

Dyadic develops the C1 fungal expression platform to produce recombinant proteins as a non-mammalian alternative. It is the most direct functional comparable to Protogenix's stated mission of replacing mammalian protein production systems.

TypeDirect peer
Description

Protalix uses its ProCellEx plant-cell-based platform to manufacture recombinant therapeutic proteins (e.g., Elelyso for Gaucher disease), directly addressing the same displacement-of-mammalian opportunity Protogenix targets.

TypeDirect peer
Description

Leaf Expression Systems uses plant-based transient expression to produce recombinant proteins and vaccines. It is a direct alternative-chassis peer competing for the same customer set of biologic developers seeking non-mammarian systems.

TypeDirect peer
Description

Eleva produces recombinant therapeutic proteins in moss-based systems (Bryotechnology). It is a niche alternative-chassis player pursuing the same biologics-manufacturing displacement thesis as Protogenix.

TypeBroad incumbent
Description

Ginkgo Bioworks is a large, publicly traded synthetic biology platform that engineers organisms (including for protein production). It is a broader incumbent with adjacent capabilities rather than a direct alternative-chassis competitor for therapeutic proteins.

TypeEmerging player
Description

Codexis engineers enzymes and proteins via directed evolution and has expanded into therapeutic protein engineering. It is a partial-overlap emerging player that competes on protein engineering platforms relevant to Protogenix's protein production mission.

TypeBroad incumbent
Description

Lonza is the world's largest biologics CDMO and the dominant mammalian (CHO) cell culture manufacturer. It represents the incumbent infrastructure Protogenix would need to displace and a potential future customer or competitor.

TypeBroad incumbent
Description

Catalent is a major global biologics CDMO with significant mammalian-cell manufacturing capacity. It is a representative incumbent in the protein production landscape that any alternative-chassis platform must compete against or partner with.

TypeEmerging player
Description

Amyris used synthetic biology and engineered yeast strains to produce high-value molecules at scale, demonstrating both the promise and the execution difficulty of alternative-chassis biology businesses — a relevant precedent for Protogenix's path.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protogenix, Inc

Biotechnology — Recombinant Protein Productionproto-genix.com

Protogenix, Inc. is a pre-revenue biotechnology company developing a proprietary recombinant protein production platform intended to replace mammalian-based systems, headquartered in Ithaca, New York, with first product launch pending.

What Protogenix, Inc does

Protogenix, Inc. is a privately held, pre-revenue biotechnology company developing a recombinant protein production platform intended to replace mammalian-based production systems. The company was founded in 2021 as a Delaware corporation and is headquartered in Ithaca, New York, operating with a small team of 1-10 employees. Its product is not yet commercialized; the corporate website (proto-genix.com) currently displays a 'Coming Soon' placeholder alongside the tagline 'The Future of Recombinant Protein Production,' and no named products, patents, or specific technical disclosures have been made public.

The company's core offering centers on a proprietary recombinant protein production technology. No specific upstream process, host system, or platform architecture has been publicly disclosed, and there are no documented patents, trademarks, certifications, or third-party validations in the input. Distribution is planned for a global footprint via direct (enterprise) sales once the platform launches, and the company has built basic digital infrastructure — a website with cookie-based analytics and a privacy-policy-anchored email/newsletter channel — to support pre-launch demand generation.

Protogenix's business model has not yet been articulated in commercial terms. The company is currently pre-revenue, with no disclosed pricing, no named customers, and no segment-level revenue mechanics. Its operating activity consists of product development and capital formation: approximately $1.97 million has been raised across four rounds between April 2023 and February 2026, including a seed round led by SOSV (formerly IndieBio) in 2023, and an SEC Form D filed in February 2026 seeking up to an additional $4.2 million under Rules 506(b) and 506(c). Use of proceeds is allocated to working capital and product development, with roughly $364,000 earmarked for payments to executive officers, directors, or promoters.

Protogenix, Inc firmographics

Firmographics
Name
Protogenix, Inc
Legal name
Protogenix Inc.
Website
https://proto-genix.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Protogenix, Inc. is a pre-revenue biotechnology company developing a proprietary recombinant protein production platform intended to replace mammalian-based systems, headquartered in Ithaca, New York, with first product launch pending.
Ownership category
akta.pro rank

Protogenix, Inc industry classification

Industry
Product category
Biotechnology — Recombinant Protein Production
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Recombinant protein production
  • Biotechnology platform
  • Protein expression systems
  • Biopharmaceutical manufacturing
  • Life sciences technology

Where Protogenix, Inc is headquartered

Location

Headquarters

HQ city
Ithaca
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Protogenix, Inc business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Biotechnology Products: Protogenix is a biotechnology company developing recombinant protein products. As a pre-revenue company currently raising seed capital, the expected revenue model would involve commercializing biotechnology products, though specific revenue mechanics are not yet disclosed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Protogenix, Inc product offering

Product offering

Core offering

Protogenix is developing a novel platform for recombinant protein production intended to replace the conventional mammalian protein expression system. The company is in pre-commercialization stage, with its product offering not yet launched (website displays a 'Coming Soon' page) and is currently raising seed capital for product development and working capital.

Product overview

Protogenix, Inc is a Delaware-incorporated biotechnology company founded in 2021 and based in Ithaca, New York, focused on recombinant protein production. The company's website currently displays a 'Coming Soon' message, indicating the product is in development stage. No specific named products, modules, or distinct offerings have been publicly launched or detailed in the available source material.

Differentiator

Problem solved

Functional benefit

Companies that use Protogenix, Inc

Customer profile

Ideal customer profiles1 record

Protogenix, Inc technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Protogenix, Inc partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Protogenix, Inc competitors and assessment

Company assessment

Direct peers

  • ORF Genetics: ORF Genetics uses barley-grain-based expression for recombinant proteins, including growth factors and cytokines. It is a direct non-mammalian production competitor in the recombinant protein space.
  • Dyadic International: Dyadic develops the C1 fungal expression platform to produce recombinant proteins as a non-mammalian alternative. It is the most direct functional comparable to Protogenix's stated mission of replacing mammalian protein production systems.
  • Protalix BioTherapeutics: Protalix uses its ProCellEx plant-cell-based platform to manufacture recombinant therapeutic proteins (e.g., Elelyso for Gaucher disease), directly addressing the same displacement-of-mammalian opportunity Protogenix targets.
  • Leaf Expression Systems: Leaf Expression Systems uses plant-based transient expression to produce recombinant proteins and vaccines. It is a direct alternative-chassis peer competing for the same customer set of biologic developers seeking non-mammarian systems.
  • Eleva Biologistics: Eleva produces recombinant therapeutic proteins in moss-based systems (Bryotechnology). It is a niche alternative-chassis player pursuing the same biologics-manufacturing displacement thesis as Protogenix.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks is a large, publicly traded synthetic biology platform that engineers organisms (including for protein production). It is a broader incumbent with adjacent capabilities rather than a direct alternative-chassis competitor for therapeutic proteins.
  • Lonza Group: Lonza is the world's largest biologics CDMO and the dominant mammalian (CHO) cell culture manufacturer. It represents the incumbent infrastructure Protogenix would need to displace and a potential future customer or competitor.
  • Catalent: Catalent is a major global biologics CDMO with significant mammalian-cell manufacturing capacity. It is a representative incumbent in the protein production landscape that any alternative-chassis platform must compete against or partner with.

Emerging players

  • Codexis: Codexis engineers enzymes and proteins via directed evolution and has expanded into therapeutic protein engineering. It is a partial-overlap emerging player that competes on protein engineering platforms relevant to Protogenix's protein production mission.
  • Amyris: Amyris used synthetic biology and engineered yeast strains to produce high-value molecules at scale, demonstrating both the promise and the execution difficulty of alternative-chassis biology businesses — a relevant precedent for Protogenix's path.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Protogenix, Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protogenix, Inc leadership team

Management profile

Number of profiles

Protogenix, Inc funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protogenix, Inc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protogenix, Inc

What does Protogenix, Inc do?

Protogenix is developing a novel platform for recombinant protein production intended to replace the conventional mammalian protein expression system. The company is in pre-commercialization stage, with its product offering not yet launched (website displays a 'Coming Soon' page) and is currently raising seed capital for product development and working capital.

Is Protogenix, Inc a public or private company?

Protogenix, Inc is a private company. It is classified as venture growth investor backed and is currently operating.

When was Protogenix, Inc founded?

Protogenix, Inc was founded in 2021. It employs 1 to 10 people.

Where is Protogenix, Inc based?

Protogenix, Inc is headquartered in Ithaca, United States, in the North America region.

How does Protogenix, Inc make money?

One revenue line is on record: biotechnology Products.

Who are Protogenix, Inc's main competitors?

Direct peers on record are ORF Genetics, Dyadic International, Protalix BioTherapeutics, Leaf Expression Systems and Eleva Biologistics. Broad incumbents are Ginkgo Bioworks, Lonza Group and Catalent. Emerging players are Codexis and Amyris.

Does Protogenix, Inc have an API?

No public API is recorded for Protogenix, Inc.

What industry is Protogenix, Inc in?

Protogenix, Inc's product category is Biotechnology — Recombinant Protein Production. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals